Halozyme Therapeutics, Inc. (HALO) — closed signal from January 26, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 26, 2026.
Predicted vs. what happened
What happened
Reached its target in 14 days.
The thesis — published January 26, 2026
Halozyme is a steadier healthcare stock that recently fell, making a short-term buy window. Analysts raised the price target to $90 because licensing of its ENHANZE drug-delivery technology is picking up, and recent sales and profits improved. Buying near support lets upcoming earnings and 2026 guidance reset expectations while limiting exposure to volatile biotech moves.
Primary drivers
- Analyst target raise points to more ENHANZE licensing deals
- Sales more than doubled compared to last year and profit improved
- Royalties from partners give multiple sources of revenue
- Lower-volatility mid-cap healthcare can gain if the sector rotates
How it played out
HALO: target reached in 14 days
Lyra published HALO at $70.79 on January 26, 2026, with 15% expected growth and a $81.40 target by April 26, 2026. The thesis pointed to more ENHANZE licensing deals, improved sales and profit, partner royalties, and a steadier healthcare profile that could gain if the sector rotated.
Inside the window, HALO rose to a $82.22 peak on February 9, 2026. That reached the target in 14 days, with a 16.2% peak gain. It did not hold that level through the end. The stock finished the window at $65.36. The thesis played out on target timing, but not on the final price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.